Skip to content
MedsAcross

Molecule

Disulfiram

Aldehyde Dehydrogenase Inhibitor
Available on requestNeurology
Presentations
2
Brands
0
Manufacturers
0
Available from stock
0

Disulfiram is an aldehyde dehydrogenase inhibitor. It is available as tablets for oral use. MedsAcross supplies Disulfiram for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Key facts

Pharmacological class
Aldehyde Dehydrogenase Inhibitor, Acetyl Aldehyde Dehydrogenase Inhibitors
ATC classification
N07BB01 Disulfiram · Other nervous system medicines, subgroup N07B, subgroup N07BBP03AA04 Disulfiram · Ectoparasiticide, subgroup P03AA
US FDA first approval
28 August 1951
EU status
Not recorded
Orphan designation
Not recorded
WHO essential medicine
Not recorded
India (CDSCO)
Not yet confirmed against CDSCO approval lists
Routes
Oral
Dosage forms
Tablet
Identifiers
UNII TR3MLJ1UAIRxCUI 3554CAS 97-77-8DrugBank DB00822Q409665

Clinical information

From the regulator-approved product information. Each section names its source.

Uses

Disulfiram is an aid in the management of selected chronic alcohol patients who want to remain in a state of enforced sobriety so that supportive and psychotherapeutic treatment may be applied to best advantage. Disulfiram is not a cure for alcoholism. When used alone, without proper motivation and supportive therapy, it is unlikely that it will have any substantive effect on the drinking pattern of the chronic alcoholic.

Source: US FDA prescribing information

Dosing overview

Disulfiram should never be administered until the patient has abstained from alcohol for at least 12 hours. Initial Dosage Schedule In the first phase of treatment, a maximum of 500 mg daily is given in a single dose for one to two weeks. Although usually taken in the morning, disulfiram may be taken on retiring by patients who experience a sedative effect. Alternatively, to minimize, or eliminate, the sedative effect, dosage may be adjusted downward. Maintenance Regimen The average maintenance dose is 250 mg daily (range, 125 mg to 500 mg), it should not exceed 500 mg daily. Note: Occasionally patients, while seemingly on adequate maintenance doses of disulfiram, report that they are able to drink alcoholic beverages with impunity and without any symptomatology.

Source: US FDA prescribing information

Contraindications

Patients who are receiving or have recently received metronidazole, paraldehyde, alcohol, or alcohol-containing preparations, e.g., cough syrups, tonics and the like, should not be given disulfiram. Disulfiram is contraindicated in the presence of severe myocardial disease or coronary occlusion, psychoses, and hypersensitivity to disulfiram or to other thiuram derivatives used in pesticides and rubber vulcanization.

Source: US FDA prescribing information

Warnings and precautions

WARNING: Disulfiram should never be administered to a patient when he is in a state of alcohol intoxication, or without his full knowledge. The physician should instruct relatives accordingly. Disulfiram should never be administered to a patient when he is in a state of alcohol intoxication, or without his full knowledge. The physician should instruct relatives accordingly. The patient must be fully informed of the disulfiram-alcohol reaction. He must be strongly cautioned against surreptitious drinking while taking the drug, and he must be fully aware of the possible consequences. He should be warned to avoid alcohol in disguised forms, i.e., in sauces, vinegars, cough mixtures, and even in aftershave lotions and back rubs. He should also be warned that reactions may occur with alcohol up to 14 days after ingesting disulfiram.

Source: US FDA prescribing information

Side effects

OPTIC NEURITIS, PERIPHERAL NEURITIS, POLYNEURITIS, AND PERIPHERAL NEUROPATHY MAY OCCUR FOLLOWING ADMINISTRATION OF DISULFIRAM. Multiple cases of hepatitis, including both cholestatic and fulminant hepatitis, as well as hepatic failure resulting in transplantation or death, have been reported with administration of disulfiram. Occasional skin eruptions are, as a rule, readily controlled by concomitant administration of an antihistaminic drug. In a small number of patients, a transient mild drowsiness, fatigability, impotence, headache, acneform eruptions, allergic dermatitis, or a metallic or garlic-like aftertaste may be experienced during the first two weeks of therapy. These complaints usually disappear spontaneously with the continuation of therapy, or with reduced dosage.

Source: US FDA prescribing information

Interactions

Disulfiram appears to decrease the rate at which certain drugs are metabolized and therefore may increase the blood levels and the possibility of clinical toxicity of drugs given concomitantly. DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS RECEIVING PHENYTOIN AND ITS CONGENERS, SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION. PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED. SUBSEQUENT TO INITIATION OF DISULFIRAM THERAPY, SERUM LEVELS OF PHENYTOIN SHOULD BE DETERMINED ON DIFFERENT DAYS FOR EVIDENCE OF AN INCREASE OR FOR A CONTINUING RISE IN LEVELS. INCREASED PHENYTOIN LEVELS SHOULD BE TREATED WITH APPROPRIATE DOSAGE ADJUSTMENT.

Source: US FDA prescribing information

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

All presentations

2 presentations of Disulfiram, sorted by availability.

MedicineManufacturerRegisterAvailability
Disulfiram 250 mg tabletOralGeneric name—US FDAAvailable on request
Disulfiram 500 mg tabletOralGeneric name—US FDAAvailable on request

Regulatory status

Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.

RegisterStatusSource
US FDAFirst approved 28 August 1951Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Conditions

Conditions linked to Disulfiram in public data. This is not a list of approved uses, see the clinical information.

Questions and answers

Is Disulfiram available for export from India?

Yes, on request. MedsAcross lists 2 presentations of Disulfiram and sources them for licensed hospitals, importers and physicians against valid import documents.

Is Disulfiram approved by the US FDA?

Yes. The US FDA first approved Disulfiram on 28 August 1951, according to Drugs@FDA.

Does Disulfiram need cold chain shipping?

No listed presentation of Disulfiram is recorded as needing a cold chain. Storage conditions are shown on each presentation page.

Which ATC class is Disulfiram in?

Disulfiram is classified under ATC code N07BB01 (Disulfiram).

References

  1. Disulfiram prescribing information (Alvogen). U.S. National Library of Medicine, DailyMed. Retrieved 29 January 2026

Request Disulfiram for export supply

Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.